Asia PacificENPublic regulatory overview
India
Market Overview Population: Approximately 1.44 billion (2024, world's largest); enormous potential patient base Healthcare System: Severely underfunded public healthcare infrastruc...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRModerate benefitCE evidence provides a strong technical-file template but does not replace the local review.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditIndirect QMS signalMDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingDossier reuse onlyThe NMPA certificate itself has limited effect, but ISO/IEC-aligned test reports, clinical evidence, risk files, and PMS data can be reused after gap assessment.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: India
- Product line: Medical devices
- Regulator / source: Regulatory Maturity: Moderate. Significant regulatory progress has been made in recent years (the Medical Device Rules 2017 represented a landmark reform), but implementation remains unstable — approval timelines are unpredictable, significant variation exists at the state level, and CDSCO (Central Drugs Standard Control Organisation) technical review capacity is still developing.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Regulatory Maturity: Moderate. Significant regulatory progress has been made in recent years (the Medical Device Rules 2017 represented a landmark reform), but implementation remains unstable — approval timelines are unpredictable, significant variation exists at the state level, and CDSCO (Central Drugs Standard Control Organisation) technical review capacity is still developing.
- Key fees: Market Characteristics: Market size approximately USD 11 billion in 2023; projected to reach USD 15 billion by 2025. Domestic manufacturers (Skanray, BPL Medical, etc.) are active in the low-to-mid range market; import dependence is high (approximately 65%). Price sensitivity is extremely high. High-end private hospitals are the primary channel for imported premium devices. The government's "Make in India" policy is driving local manufacturing, creating a growing trend toward restricting imports.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 1.44 billion (2024, world's largest); enormous potential patient base
- Healthcare System: Severely underfunded public healthcare infrastructure; private hospitals account for approximately 80% of healthcare delivery. Universal health insurance (PM-JAY / Ayushman Bharat) covers approximately 500 million low-income individuals, but actual coverage quality is limited; approximately 60% of healthcare expenditure is out-of-pocket.
- Market Characteristics: Market size approximately USD 11 billion in 2023; projected to reach USD 15 billion by 2025. Domestic manufacturers (Skanray, BPL Medical, etc.) are active in the low-to-mid range market; import dependence is high (approximately 65%). Price sensitivity is extremely high. High-end private hospitals are the primary channel for imported premium devices. The government's "Make in India" policy is driving local manufacturing, creating a growing trend toward restricting imports.
- Regulatory Maturity: Moderate. Significant regulatory progress has been made in recent years (the Medical Device Rules 2017 represented a landmark reform), but implementation remains unstable — approval timelines are unpredictable, significant variation exists at the state level, and CDSCO (Central Drugs Standard Control Organisation) technical review capacity is still developing.
Regulatory Authority
- Competent Authority: CDSCO (Central Drugs Standard Control Organisation), under the Ministry of Health and Family Welfare (MoHFW)
- Official Portals: https://cdsco.gov.in; Online application system: https://sugam.egateway.gov.in
- Key Regulations:
- Medical Device Rules 2017 (MDR 2017, effective June 2017; replaced Schedule M III of the Drugs and Cosmetics Act)
- Drugs and Cosmetics Act 1940 (parent legislation for MDR 2017)
- Medical Device (Amendment) Rules 2020 and 2022 (multiple subsequent amendments)
- In Vitro Diagnostics Device Rules 2017 (separate rules for IVDs)
- 2022 expansion of the medical device definition bringing additional products under regulatory scope
Device Classification System
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Class A | Lowest risk | EU Class I / FDA Class I | Declaration/registration filing system; handled by State Licensing Authority (SLA); relatively straightforward |
| Class B | Low-moderate risk | EU Class IIa / FDA Class II | Registration license system; approved by State Licensing Authority |
| Class C | Moderate-high risk | EU Class IIb / FDA Class III | Registration license system; CDSCO headquarters review; clinical evidence typically required |
| Class D | Highest risk | EU Class III / FDA PMA | Registration license system; most rigorous CDSCO headquarters review; clinical investigation data required |
Note: MDR 2017 has progressively expanded the scope of "regulated devices" — only 23 categories were included in 2017; since 2022, virtually all medical devices require registration. Refer to CDSCO's Medical Device Classification Guidelines for classification determinations.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.